Metagenomi Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period
Metagenomi Therapeutics, Inc. (MGX) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period of 12.05 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod · last filed 2026-08-10
- Metagenomi Therapeutics, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2026-06-30 was 11.36K shares.
- Metagenomi Therapeutics, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2026-03-31 was 692.00 shares.
- Metagenomi Therapeutics, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for the quarter ending 2024-03-31 was 6.84K shares.
- Metagenomi Therapeutics, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2025 was 87.25K shares, a 7.38% increase from fiscal 2024.
- Metagenomi Therapeutics, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period for fiscal 2024 was 81.25K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period 12 month |
|---|---|---|---|
| 2026-06-30 | 11.36K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | 12.05K shares 10-Q · filed 2026-08-10 | |
| 2026-03-31 | 692.00 shares 10-Q · filed 2026-05-11 | ||
| 2025-12-31 | 87.25K shares 10-K · filed 2026-03-05 | ||
| 2024-12-31 | 81.25K shares 10-K · filed 2025-03-17 | ||
| 2024-03-31 | 6.84K shares 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |